Scroll down

Invention

The invention relates to the use of Mad7, a Type V CRISPR nuclease, for genome editing in plant cells. Type V CRISPR systems are two-component systems requiring a nuclease and a crRNA for guidance. The type V CRISPR system based on the nuclease Mad7 was found to be highly effective in plant cell genome editing, and more effective as compared to a CRIPSR system based on another type V CIRSPR nuclease, Cpf1.

Benefit

Genome editing technologies are rapidly emerging. CRISPR system nucleases are highly agile and easily programmable. Type V CRISPR nucleases are beneficial as they on use a single RNA element for guidance: a crRNA. The type V nuclease Mad7 was found highly effective in plant cells in inducing genomic variation.

Vision

Understanding the function of genes is essential for efficient breeding of improved crops. Efficient targeted genome editing technologies are important research tools in gene validation and may be used for introduction of new traits in crop germplasm. The present invention contributes thereto.

Patent

Click on the link for an overview of the patent family in the European Patent Register: WO2020/011985

Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.

Contact us

Would you like to explore the possibilities for obtaining a license for this technology? You can contact our licensing team by mail.

Would you like to know more about our technologies and licensing possibilities? Visit our webpage about Licensing KeyGene’s proprietary technologies.